<!DOCTYPE html>
<html>

<head>
    <title>GSK Master Template</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <meta name="format-detection" content="telephone=no" />
    <meta name="msapplication-tap-highlight" content="no" />
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />

    <link rel="stylesheet" href="../shared/css/jquery-ui.css" type="text/css" charset="utf-8" />
    <link rel="stylesheet" href="../shared/css/core.css" type="text/css" charset="utf-8" />
    <link rel="stylesheet" href="../shared/css/custom.css" type="text/css" charset="utf-8" />
    <link rel="stylesheet" href="../shared/css/presentation.css" type="text/css" charset="utf-8" />
    <link rel="stylesheet" href="css/local.css" type="text/css" charset="utf-8" />
</head>

<body>
    <div id="container" class="customSwipe">
        <!-- Left and right double click navigation -->
        <!--<div id="doubleClickRight" class="navBumper"></div>-->
        <!-- Portrait mode double click zoom -->
        <!--<div id="doubleClickCentre"></div>-->

        <!-- slide html -->
        <div class="mainContent">
            <div class="left_menu_1">
                <ul>
                    <li class="icon_6 gotoSlide" data-fields="TrackElementId|TrackElementDescription|TrackElementType"
                        data-description="Exacerbation and OCS use reduction (REALITI-A)|Exacerbation and OCS reduction (FR ATU)|Animation"
                        data-presentation="Nucala_eDetail_Bridge_campaign_2020_MF1.0_MAIN"
                        data-slide="Nucala_eDetail_Bridge_campaign_2020_MF1.0_007"></li>
                    <li class="div_img"></li>
                    <li class="icon_7_active gotoSlide"
                        data-presentation="Nucala_eDetail_Bridge_campaign_2020_MF1.0_MAIN"
                        data-slide="Nucala_eDetail_Bridge_campaign_2020_MF1.0_008"></li>
                </ul>
            </div>
            <div class="pageHeading">Nucala: Associated with real-life<br>
                protection from exacerbations<sup>*</sup> and<br>
                maintenance OCS<sup>11</sup>
            </div>

            <div class="sub_head">
                REALITI-A INTERIM ANALYSIS<sup>11</sup>
            </div>

            <div class="box_1">
                <div class="arrow_img"></div>
                <div class="head_number">69%</div>
                <div class="head_text">REDUCTION IN EXACERBATIONS</div>
                <div class="para_text">
                    (n=367)<br>
                    Rate ratio: 0.31 CI: 0.27–0.35<br>
                    4.63 at baseline (over the previous<br>
                    12 months) vs. 1.43 at 12 months<br><br>
                    Exacerbation rate at 12 months<sup>11</sup>
                </div>
            </div>


            <div class="box_2">
                <div class="arrow_img"></div>
                <div class="head_number">52%</div>
                <div class="head_text">REDUCTION IN MEDIAN<br>
                    MAINTENANCE OCS DOSE**</div>
                <div class="para_text">
                    (n=143)<br>
                    (95% CI: 50–75)<br>
                    10mg at baseline vs. 5mg at 12 months<sup>11</sup>
                </div>

                

                <div class="p1_img"></div>
                <div class="plus_icon gotoSlide"
                    data-fields="TrackElementId|TrackElementDescription|TrackElementType"
                    data-description="Exacerbation and OCS use reduction (REALITI-A)|Patient - Frequent exacerbations|Popup"
                    data-presentation="Nucala_eDetail_Bridge_campaign_2020_MF1.0_MAIN"
                    data-slide="Nucala_eDetail_Bridge_campaign_2020_MF1.0_001.1"></div>

                <div class="p2_img"></div>
                <div class="plus_icon_1 gotoSlide"
                    data-fields="TrackElementId|TrackElementDescription|TrackElementType"
                    data-description="Exacerbation and OCS use reduction (REALITI-A)|Patient - OCS dependent|Popup"
                    data-presentation="Nucala_eDetail_Bridge_campaign_2020_MF1.0_MAIN"
                    data-slide="Nucala_eDetail_Bridge_campaign_2020_MF1.0_001.3"></div>
            </div>

            <div class="summ_content">
                <div class="head_summ">STUDY LIMITATIONS</div>
                <div class="text_summ">These data are a prespecified interim analysis of 368 patients<br>
                    who completed 12 months of follow-up as of February 2019.<br>
                    This analysis may not reflect the results from the final dataset.</div>


            </div>




            <div class="foot_t">
                <p>ATU, Temporary Authorisation for Use; CI, confidence interval; ED, emergency department; OCS, oral
                    corticosteroid; RA, REALITI-A<br>
                    *Defined as deterioration in asthma requiring use of systemic corticosteroids and/or an ED visit
                    and/or hospital admission<br>
                    **52% is the median percent reduction from baseline in average daily dose of maintenance OCS</p>

            </div>

        </div>

        </div>
        <!-- <div class="zincCode">
            XX/XX/0000/00
        </div><br />
        <div class="preparation">
            Date of Preparation: April 2019
        </div> -->
        <!-- end of slide html -->

        <!-- mtgsk html -->
        <div class="logo_top"></div>
        <!-- <div class="header">
            <div class="mainLogo" id="logo"></div>
        </div> -->
        <div class="footer">
            <div class="brandLogo" id="footerLogo"></div>
        </div>
        <div class="button_b2 openDialog" data-fields="TrackElementId|TrackElementDescription|TrackElementType"
                    data-description="Exacerbation and OCS use reduction (REALITI-A)|REALITI-A Study design|Animation"
                    data-dialog="#dialog">REALITI-A STUDY DESIGN AND<br>
                    BASELINE CHARACTERISTICS</div>
        <div class="navBottom">
            <div id="home" class="gotoSlide"></div>
            <!-- <div id="menu" class="gotoSlide logEmbedded" data-description="Embedded Menu"></div> -->
            <div id="pi" class="gotoSlide logEmbedded" data-description="Embedded PI"></div>
            <div id="references" class="gotoSlide logEmbedded" data-description="Embedded References"></div>
            <div id="email"></div>
            <div id="summary" class="gotoSlide logEmbedded display"
                data-presentation="Nucala_eDetail_Bridge_campaign_2020_MF1.0_MAIN"
                data-slide="Nucala_eDetail_Bridge_campaign_2020_MF1.0_013"></div>
            <div id="objection" class="gotoSlide logEmbedded" data-description="Embedded Objections"></div>
            <div id="resource" class="gotoSlide logEmbedded display"
                data-presentation="Nucala_Edetail_Real_Life_2020_MF1.0_MAIN"
                data-slide="Nucala_Edetail_Real_Life_2020_MF1.0_RES"></div>
            <div id="quickres" class="gotoSlide logEmbedded"></div>
        </div>
        <!-- end mtgsk html -->



        <div id="dialog" class="dialog hidden" data-width="2048" data-height="100" data-description="Parent popup">
            <div class="title_practice">REALITI-A: Study design and<br>
                baseline characteristics</div>
            <div class="popup_content">
                <div id="section_1">
                    <div class="content_1">
                        INTERIM ANALYSIS<sup>11</sup>
                        <p>These data are a prespecified interim analysis of 368
                            patients who completed 12 months of follow-up. This
                            analysis may not reflect the results from the final dataset.</p>
                    </div>
                    <div class="content_1">
                        DESCRIPTION<sup>11</sup>
                        <p>Ongoing, 2-year, prospective, multinational, single-arm,
                            observational cohort study assessing the real-world
                            effectiveness and pattern of use of NUCALA 100mg every
                            4 weeks in adult patients with SEA who met the eligibility
                            requirements to initiate NUCALA. Data were collected
                            prospectively at usual asthma healthcare visits. A 12-month
                            period of relevant medical data was required prior to
                            enrolment and collected retrospectively. Baseline visit was
                            first administration of NUCALA.</p>
                    </div>
                    <div class="content_1a">
                        OBJECTIVES<sup>11</sup>
                        <p>Assessed 12-month post-treatment period vs. <br>12-month
                            pre-treatment period (baseline); primary: exacerbation rate;
                            secondary: maintenance OCS use among users at baseline.</p>
                    </div>

                    <div class="content_1b">
                        STUDY POPULATION, N=368<sup>11</sup>
                        <p>During the 12-month follow-up, 19% discontinued
                            treatment with NUCALA (2% due to an adverse event; 4%
                            lack of efficacy; 13% other).</p>
                        <p>Real-world studies are designed to evaluate associations
                            among variables and not to definitively establish causality.
                            These limitations are important when interpreting results:
                            retrospective analysis, lack of comparator arm, small group
                            of patients and differences in patient populations and data
                            collection vs. randomised controlled trials.</p>
                    </div>

                    <div class="down_arrow shake-bottom"></div>
                </div>

                <div id="section_2">
                    <div class="up_arrow shake-top"></div>
                    <div class="content_2">
                        SAFETY POPULATION, N=368<sup>11</sup>
                        <p>Any drug-related AE 14%, SAE &lt;1%, AE leading to
                            discontinuation 3%; most common AE reported was
                            headache (6%).</p>
                    </div>
                    <div class="foot_text">
                        AE, adverse event; FEV<sub>1</sub>, forced expiratory volume in one second; GERD,
                        gastroesophageal reflux disease; OCS, oral corticosteroid; SAE, serious adverse event
                    </div>

                    <div class="right_content">
                        <table class="tg">
                            <tr>
                                <th class="tg-g59i" colspan="2">SUMMARY OF BASELINE
                                    CHARACTERISTICS<sup>11</sup></span></th>
                            </tr>
                            <tr>
                                <td class="tg-xogg"></td>
                                <td class="tg-xogg"><span style="font-weight:bold">Total population (N=368)</span></td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">Mean age</td>
                                <td class="tg-0pky">53.1 ± 13.72 years</td>
                            </tr>

                            <tr>
                                <td class="tg-0pky">Geography<br>Europe<br>Canada<br>United States</td>
                                <td class="tg-0pky">
                                    <ul>
                                        <li></li>
                                        <li>320</li>
                                        <li>40</li>
                                        <li>8</li>
                                    </ul>
                                </td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">Duration of severe asthma</td>
                                <td class="tg-0pky">20.03 ± 15.13 years</td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">Mean number of exacerbations prior to treatment index</td>
                                <td class="tg-0pky">4.7 ± 4.09</td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">Geometric mean blood eosinophils</td>
                                <td class="tg-0pky">370 cells/μL</td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">Current OCS use</td>
                                <td class="tg-0pky">48%</td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">Baseline present predicted FEV<sub>1</sub></td>
                                <td class="tg-0pky">64.4% ± 20.3%</td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">Co-morbidities (>35%)<br>Hay fever<br>Chronic sinusitis<br>Nasal
                                    polyps<br>GERD</td>
                                <td class="tg-0pky">
                                    <ul>
                                        <li></li>
                                        <li>52%</li>
                                        <li>39%</li>
                                        <li>38%</li>
                                        <li>37%</li>
                                    </ul>
                                </td>
                            </tr>

                        </table>
                    </div>

                </div>
            </div>
        </div>




    </div>
    <!-- Background settings required for pdf style portrait mode zoom -->
    <div class="bg" id="bg"></div>
    <script src="../shared/js/jquery-3.1.0.min.js"></script>
    <script src="../shared/js/jquery-ui.js"></script>
    <script src="../shared/js/jquery.ui.touch-punch.js"></script>
    <script src="../shared/js/veeva-library.js"></script>
    <script src="../shared/js/config.json"></script>
    <script src="../shared/js/fastclick.min.js"></script>
    <script src="../shared/js/hammer.min.js"></script>
    <script src="../shared/js/iscroll.js"></script>
    <script src="../shared/js/mt.js"></script>
    <script src="../shared/js/presentation.js"></script>
    <script src="../shared/js/race.js"></script>
    <script src="js/local.js"></script>
    <!-- <script src="../shared/posChanger-3.4.js"></script>
    <script src="../shared/specific.js"></script> -->
</body>

</html>